{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:26:04Z","timestamp":1790141164034,"version":"4.0.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jacl.2020.01.006","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T14:53:33Z","timestamp":1579877613000},"page":"e1-e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0234-6366","authenticated-orcid":false,"given":"Raman","family":"Puri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devaki","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdish Chander","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshed J.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi R.","family":"Kasliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saibal","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6368-1179","authenticated-orcid":false,"given":"Harsh","family":"Wardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-3825","authenticated-orcid":false,"given":"Narendra Nath","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshaya","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-470X","authenticated-orcid":false,"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonika","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arumugam","family":"Muruganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gururaj Balvantrao","family":"Sattur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8170-2845","authenticated-orcid":false,"given":"Madhur","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder Pal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Kumar","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-7178","authenticated-orcid":false,"given":"Rashmi","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2020.01.006_bib1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/bmj.328.7443.807","article-title":"Burden of non-communicable diseases in South Asia","volume":"328","author":"Ghaffar","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2020.01.006_bib2","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/CIRCULATIONAHA.114.008720","article-title":"Global and regional patterns in cardiovascular mortality from 1990 to 2013","volume":"132","author":"Roth","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.114.008729","article-title":"Cardiovascular diseases in India: current epidemiology and future directions","volume":"133","author":"Prabhakaran","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacl.2020.01.006_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/atm.2017.10.18","article-title":"Asian-Indians: a review of coronary artery disease in this understudied cohort in the United States","volume":"6","author":"Ardeshna","year":"2018","journal-title":"Ann Transl Med"},{"issue":"5","key":"10.1016\/j.jacl.2020.01.006_bib6","doi-asserted-by":"crossref","first-page":"e96808","DOI":"10.1371\/journal.pone.0096808","article-title":"Prevalence of dyslipidemia in urban and rural India: the ICMR\u2013INDIAB Study","volume":"9","author":"Joshi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2020.01.006_bib7","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2020.01.006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-74-1-1","article-title":"Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study","volume":"74","author":"Kannel","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2020.01.006_bib9","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.01.006_bib10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.01.006_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.01.006_bib12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL-C cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.01.006_bib13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2020.01.006_bib14","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib15","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib16","first-page":"S7","article-title":"Lipid Association of India expert consensus statement on management of dyslipidemia in Indians 2016: Part 1","volume":"64","author":"Iyengar","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.jacl.2020.01.006_bib17","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.006_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT Trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2020.01.006_bib19","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a pre-specified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.01.006_bib20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.01.006_bib21","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.01.006_bib22","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.01.006_bib23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.01.006_bib24","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2020.01.006_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance\u2013 an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jacl.2020.01.006_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2020.01.006_bib27","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2020.01.006_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries- findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.01.006_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.01.006_bib30","first-page":"56","article-title":"Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2","volume":"12","author":"Iyengar","year":"2017","journal-title":"Clin Lipidol"},{"issue":"Suppl 2","key":"10.1016\/j.jacl.2020.01.006_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacl.2020.01.006_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2018.06.821","article-title":"Extreme-risk category: high prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-C-cholesterol less than 55\u00a0mg\/dL","volume":"275","author":"Rallidis","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.01.006_bib33","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1161\/CIRCULATIONAHA.108.819201","article-title":"Fatal and nonfatal cardiovascular disease and the use of therapies for secondary prevention in a rural region of India","volume":"119","author":"Joshi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.01.006_bib35","first-page":"1007","article-title":"Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India","volume":"5","author":"Sharma","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jacl.2020.01.006_bib36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2020.01.006_bib37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.006_bib38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jacl.2020.01.006_bib39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.01.006_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacl.2020.01.006_bib41","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.01.006_bib42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2020.01.006_bib43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7555\/JBR.29.20150052","article-title":"PCSK9 and triglyceride-rich lipoprotein metabolism","volume":"29","author":"Druce","year":"2015","journal-title":"J Biomed Res"},{"key":"10.1016\/j.jacl.2020.01.006_bib44","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2020.01.006_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jacl.2015.12.004","article-title":"JCL roundtable: PCSK9 inhibitors in clinical practice","volume":"10","author":"Brown","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.01.006_bib46","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.01.006_bib47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.116.025080","article-title":"Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism","volume":"135","author":"Watts","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2018.07.017","article-title":"Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: analysis of the ODYSSEY LONG TERM trial","volume":"276","author":"Taskinen","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.01.006_bib49","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11883-013-0360-6","article-title":"Update on lipoprotein(a) as a cardiovascular risk factor and mediator","volume":"15","author":"Boffa","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2020.01.006_bib50","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1253\/circj.CJ-15-0999","article-title":"Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutations","volume":"80","author":"Tada","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2020.01.006_bib51","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacbts.2016.08.007","article-title":"Lipoprotein (a): a frustrating final frontier in lipid management?","volume":"1","author":"Libby","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacl.2020.01.006_bib52","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.01.006_bib53","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/bcp.12905","article-title":"Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms","volume":"81","author":"Sahebkar","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2020.01.006_bib54","series-title":"PRALUENT (alirocumab) [package insert]","year":"2017"},{"key":"10.1016\/j.jacl.2020.01.006_bib55","series-title":"REPATHA (evolocumab) [package insert]","year":"2018"},{"key":"10.1016\/j.jacl.2020.01.006_bib56","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.01.006_bib57","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.01.006_bib58","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib59","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomized controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2020.01.006_bib60","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib61","unstructured":"Koren MJ, Sabatine MS, Giugliano RP, et al. Final report of the OSLER-1 study: long-term evolocumab for the treatment of hypercholesterolemia. Abstract 118, American Heart Association Scientific Sessions, 10-12 November 2018, Chicago, USA."},{"key":"10.1016\/j.jacl.2020.01.006_bib62","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2020.01.006_bib63","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1016\/j.jacc.2018.04.015","article-title":"Critical appraisal of the 2018 ACC scientific sessions late-breaking trials from a statistician\u2019s perspective","volume":"71","author":"Pocock","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.006_bib64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES Trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.006_bib70","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","article-title":"PCSK9 inhibitors: economics and policy","volume":"70","author":"Hlatky","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.006_bib71","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1161\/CIRCULATIONAHA.115.015373","article-title":"A cluster-randomized, controlled trial of a simplified multifaceted management program for individuals at high cardiovascular risk (SimCard Trial) in Rural Tibet, China, and Haryana, India","volume":"132","author":"Tian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib72","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jacc.2011.10.901","article-title":"The Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): a cluster randomized trial","volume":"59","author":"Joshi","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.006_bib73","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jama.2017.21906","article-title":"Effect of a quality improvement intervention on clinical outcomes in patients in India with acute myocardial infarction: the ACS QUIK randomized clinical trial","volume":"319","author":"Huffman","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2020.01.006_bib74","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2020.01.006_bib75","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/eurheartj\/ehx710","article-title":"Highest risk\u2013highest benefit strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies","volume":"39","author":"Annemans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2020.01.006_bib76","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.006_bib77","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk of cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.006_bib78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"3 Suppl","key":"10.1016\/j.jacl.2020.01.006_bib79","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"National Lipid Association expert panel on familial hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association expert panel on familial hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.01.006_bib80","doi-asserted-by":"crossref","first-page":"e013225","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2020.01.006_bib81","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2020.01.006_bib82","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","article-title":"Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART registry (Spanish familial hypercholesterolaemia cohort study)","volume":"36","author":"Perez de Isla","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2020.01.006_bib83","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacl.2017.12.014","article-title":"Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy","volume":"12","author":"Galema-Boers","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.01.006_bib84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.08.007","article-title":"Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry","volume":"289","author":"Duell","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.01.006_bib85","article-title":"Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action","author":"Wilemon","year":"2020","journal-title":"JAMA Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:34:49Z","timestamp":1761831289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287420300064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1933287420300064"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2020.01.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2020.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}